Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(1.01) per share. This is a 68.33 percent decrease over losses of $(0.60) per share from the same period last year.
WisdomTree Completes Repurchase Of Non-Voting Preferred Shares Convertible Into 13.1M Shares Of WisdomTree Common Stock From A Subsidiary Of The World Gold Council
Repurchase is 7% accretive to current 2024 consensus EPS estimatesWisdomTree, Inc. (NYSE:WT) ("WisdomTree" or the "Company"), a global financial innovator, today announced the completion of the repurchase of its
